(Q42907761)

10 November 2017

Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study (English)

1 reference

10 November 2017

1 reference

Vaishali Sanchorawala

series ordinal

1

1 reference

10 November 2017

3

1 reference

10 November 2017

Karen Quillen

2

0 references

author name string

Nancy T Andrea

series ordinal

4

1 reference

PMC publication ID

3232278

10 November 2017

David C Seldin

series ordinal

5

1 reference

10 November 2017

22 August 2011

1 reference

10 November 2017

1 reference

10 November 2017

96

1 reference

10 November 2017

12

1 reference

10 November 2017

1890-1892

1 reference

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study

10 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

NF-kappa B as a therapeutic target in multiple myeloma

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3232278

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21859734

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21859734

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3324/HAEMATOL.2011.049858

1 reference

10 November 2017

1 reference

PMC publication ID

3232278

10 November 2017

PubMed publication ID

21859734

1 reference

PMC publication ID

3232278